Screener
Pelthos Therapeutics PTHS Q3 2026 earnings
Reported November 12, 2026 · Before market open
Revenue$15.4MMiss by $1.5M
EPS-$2.04Beat by $1.04
Revenue estimate$16.9M
EPS estimate-$3.08
“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”
Next report
Date not yet announcedValuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Pelthos Therapeutics report Q3 2026 earnings?
- Pelthos Therapeutics (PTHS) reported Q3 2026 earnings on November 12, 2026 before market open.
- What were Pelthos Therapeutics's Q3 2026 revenue and EPS?
- Pelthos Therapeutics reported revenue of $15.4M and eps of $-2.04 for Q3 2026.
- Did Pelthos Therapeutics beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $16.9M by $1.5M. EPS beat the consensus estimate of $-3.08 by $1.04.
- How did Pelthos Therapeutics's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 107.9% from $7.4M a year earlier and eps grew 61.5% from $-5.30.
- Where can I find Pelthos Therapeutics's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001919246-26-000134) and the 10-Q periodic report (0001919246-26-000135) directly on SEC EDGAR. The filing index links above go to sec.gov.
